AccScience Publishing / ITPS / Volume 3 / Issue 1 / DOI: 10.36922/itps.v3i1.906
Cite this article
4
Download
61
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW

Importance and Feasibility of Point-of-care Testing in Takayasu’s Arteritis

Sakshi Mehta1 Veena Dhawan*
Show Less
1 Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

This article belongs to the Special Section: Point-of-Care Testing Tool Development in Health and Disease.

INNOSC Theranostics and Pharmacological Sciences 2020, 3(1), 906 https://doi.org/10.36922/itps.v3i1.906
Submitted: 26 February 2020 | Accepted: 17 April 2020 | Published: 30 April 2020
© 2020 by the Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Takayasu’s arteritis (TAK) is known to be a unique, rare, and chronic vasculitis disease that affects large elastic arteries 
such as aorta and its major branches. TAK is characterized by adventitial thickening, weak pulses and ocular disturbances. The prognosis and diagnosis of TAK are challenging due to the non-specific, silent, or paucisymptomatic presentation of the disease. The effective understanding of TAK lies with the timely recognition of the symptoms and a rapid diagnosis of the disease. Point-of-care testing (POCT) is vital for the quick and reliable detection of parameters near bedside for disease diagnosis, assessment, monitoring, and therapeutics management. Ultrasonography is the most reliable POCT technique. Moreover, erythrocyte sedimentation rate and C-reactive protein assay are the two most valuable non-imaging POCT tests used to determine inflammation and onset of the disease. Other potential biomarkers such as matrix metalloproteinases, soluble receptor for advanced glycation end products, interleukin (IL)-6, and IL-18 have also been advocated for tracking the progression of TAK. Furthermore, vasculitis associatedanti-neutrophil cytoplasmic antibodies have also been reported to reflect the inflammatory phase of the disease. Therefore, the development of POCT based on these blood-based biomarkers may help in quick clinical decision-making for early diagnosis of TAK and targeted therapeutics to improve clinical outcome in patients suffering from this debilitating disease.

Keywords
Takayasu’s arteritis
Point-of-care testing
Biomarkers
Imaging techniques
Conflict of interest
The authors declare that they have no conflict of interest.
References
[1]

Kerr, G.S.; Hallahan, C.W.; Giordano, J.; Leavitt, R.Y.; Fauci,A.S.; Rottem M, Hoffman, G.S. Takayasu Arteritis. Ann. Intern. Med., 1994, 120, 919–29.

[2]

Sekiguchi, M.; Suzuki, J. An Overview on Takayasu Arteritis. Heart Vessels. 1992, 7, 6–10.

[3]

Arnaud, L.; Haroche, J.; Mathian, A.; Gorochov, G.; Amoura, Z. Pathogenesis of Takayasu’s Arteritis: A 2011 Update. Autoimmun. Rev., 2011, 11, 61–7.

[4]

Jennette, J.C.; Falk, R.J.; Andrassy, K.; Bacon, P.A.; Churg, J.; Gross, W.L.; Hagen, E.C.; Hoffman, G.S.; Hunder, G.G.; Kallenberg, C.G. Nomenclature of Systemic Vasculitis. Proposal of an International Consensus Conference. Arthritis Rheum., 1994, 37, 187–92.

[5]

Takayasu, M. A Case with Peculiar Changes of the Retinal Central Vessels. Acta Soc. Ophthal. Jpn., 1908, 12, 554–5.

[6]

Numano, F.; Kakuta, T. Takayasu Arteritis-five Doctors in the History of Takayasu Arteritis. Int. J. Cardiol., 1996, 54(Suppl), S1–10.

[7]

Sinmi, Y. A case of takayasu’s arteritis. Sogo Gannka., 1942, 36, 1404–10.

[8]

Johnston, S.L.; Lock, R.J.; Gompels, M.M. Takayasu Arteritis: A Review. J. Clin. Pathol., 2002, 55, 481–6.

[9]

Arend, W.P.; Michel, B.A.; Bloch, D.A.; Hunder, G.G.; Calabrese, L.H.; Edworthy, S.M.; Fauci, A.S.; Leavitt, R.Y.; Lie, J.T.; Lightfoot, R.W. Jr., The American College of Rheumatology 1990 Criteria for the Classification of Takayasu Arteritis. Arthritis Rheumat., 1990, 33(8), 1129–34

[10]

Jain, S.; Sharma, N.; Singh, S.; Bali, H.K.; Kumar, L.; Sharma, B.K. Takayasu Arteritis in Children and Young Indians. Int J Cardiol., 2000, 75, S153–7.

[11]

Brunner, J.; Feldman, B.M.; Tyrrell, P.N.; KuemmerleDeschner, J.B.; Zimmerhackl, L.B.; Gassner, I.; Benseler, S.M. Takayasu Arteritis in Children and Adolescents. Rheumatology, 2010, 49, 1806–14.

[12]

Cakar, N.; Yalcinkaya, F.; Duzova, A.; Caliskan, S.; Sirin, A.; Oner, A.; Baskin, E.; Bek, K.; Soylu, A.; Fitoz, S.; Bayazit, A.K.; Bircan, Z.; Ozen, S.; Uncu, N.; Ekim, M. Takayasu Arteritis in Children. J. Rheumatol., 2008, 35, 913–9.

[13]

Moriwaki, R.; Noda, M.; Yajima, M.; Sharma, B.K.; Numano, F. Clinical Manifestations of Takayasu Arteritis in India and Japan New Classification of Angiographic Findings. Angiology, 1997, 48, 369–79.

[14]

Kinare, S.G. Aortitis in Early Life in India and its Association with Tuberculosis. J. Pathol., 1970, 1, 69–76.

[15]

Pantell, R.H.; Goodman, B.W. Takayasu’s Arteritis: The Relationship with Tuberculosis. Pediatric, 1981, 67, 84–8.

[16]

Chogle, A.R.; Shah, D.A.; Cerejo, C. Analysis of Evidence to Determine the Link between Takayasu’s Arteritis and Tubercilosis.Ind. J. Rheumat., 2015, 10, 2–9.

[17]

Sagar, S.; Ganguly, N.K.; Koicha, M.; Sharma, B.K. Immuno Pathogenesis of Takayasu Arteritis. Heart Vessels., 1992, 7, 85–90.

[18]

Yoshida, M.; Kimura, A.; Katsuragi, K.; Numano, F.; Sasazuki, T. DNA Typing of HLA-B Gene in Takayasu’s Arteritis. Tissue Antigens, 1993, 42, 87–90.

[19]

Terao, C.; Yoshifuji, H.; Ohmura, K.; Murakami, K.; Kawabata, D.; Yurugi, K.; Tazaki, J.; Kinoshita, H.; Kimura, A.; Akizuki, M.; Kawaguchi, Y.; Yamanaka, H.; Miura, Y.; Maekawa, T.; Saji, H.; Mimori, T.; Matsuda, F. Association of Takayasu Arteritis with HLA-B 67:01 and Two Amino Acids in HLA-B Protein. Rheumatology, 2013, 52, 1769–74.

[20]

Sahin, Z.; Bicakcigil, M.; Aksu, K.; Kamali, S.; Akar, S.; Onen, F.; Karadag, O.; Ozbalkan, Z.; Ates, A.; Te Ozer, H.; Yilmaz, V. Takayasu’s Arteritis is Associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Res. Ther., 2012, 14, R27.

[21]

Noris, M. Pathogenesis of Takayasu’s Arteritis. J. Nephrol., 2001, 14, 506–13.

[22]

Inder, S.J.; Bobryshev, Y.V.; Cherian, S.M.; Wang, A.Y.; Lord, R.S.; Masuda, K.; Yutani, C. Immunophenotypic Analysis of the Aortic Wall in Takayasu’s Arteritis: Involvement of Lymphocytes, Dendritic Cells and Granulocytes in Immuno-inflammatory Reactions. Cardiovasc. Surg., 2000, 8, 141–8.

[23]

Kim, E.S.; Beckman, J. Takayasu Arteritis: Challenges in Diagnosis and Management. Heart, 2018, 104, 558–65.

[24]

Mason, J.C. Takayasu Arteritis Advances in Diagnosis and Management. Nat. Rev. Rheumatol., 2010, 6, 406–15.

[25]

Ishikawa, K. Diagnostic Approach and Proposed Criteria for the Clinical Diagnosis of Takayasu’s Arteriopathy. J. Am. Coll. Cardiol., 1988, 12, 964–72.

[26]

Sharma, B.K.; Jain, S.; Suri, S.; Numano, F. Diagnostic Criteria for Takayasu Arteritis. Int. J. Cardiol., 1996, 54(Suppl), S141–7.

[27]

Russo, R.A.; Katsicas, M.M. Takayasu Arterities. Front. Pediatr., 2018, 6, 265.

[28]

Dejaco, C.; Ramiro, S.; Duftner, C.; Besson, F.L.; Bley, TA.; Blockmans, D.; Cimmino, M.A.; Clark, E.; Dasgupta, B. EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice. Ann. Rheum. Dis., 2018, 77, 636–43.

[29]

Price, C.P. Point-of-care Testing Impact on Medical Outcomes. Clin. Lab. Med., 2001, 45, 1104–21.

[30]

O’Kane, M. Point of Care Testing Current and Emerging Perspectives. Point Care J. Near Patient Test. Technol., 2014, 31, 1–5.

[31]

Gialams, S.; St John, A.; Laurence, C.O. Point-of-care Testing for Patients with Diabetes, Hyperlipidaemia or Coagulation Disorders in the General Practice Setting: A Systematic Review. Fam. Pract., 2010, 27, 17–24.

[32]

Vashist, S.K.; Luppa, P.B.; Yeo, L.Y.; Ozcan, A.; Luong, J.H. Emerging Technologies for Next-Generation Point-of-Care Testing. Trends Biotechnol., 2015, 33, 692–705.

[33]

Alibaz-Oner, F.; Yentür, S.P.; Saruhan, Park YB, Lee SK, Direskeneli G, Direskeneli H. Serum Cytokine Profiles in Takayasu’s Arteritis: Search for Biomarkers. Clin. Exp. Rheumatol., 2015, 33(2 Suppl 89), S32–5.

[34]

Barta, L.; Kanji, T.; Malette, J.; Pagnoux, C. Imaging Modalities for the Diagnosis and Disease Activity Assessment of Takayasu’s Arteritis: A Systematic Review and Meta-analysis. Autoimmune. Rev., 2018, 17, 175–87.

[35]

Choe, Y.H.; Han, B.K.; Koh, E.M.; Kim. D.K.; Do. Y.S.; Lee. W.R. Takayasu’s Arteritis: Assessment of Disease Activity with Contrast Enhanced MRI Imaging. Am. J. Roentgenol., 2000, 175, 205–11.

[36]

Tso, E.; Flamm, S.D.; White, R.D.; Schvartzman, P.R.; Mascha, E.; Hoffman, G.S. Takayasu Arteritis: Utility and Limitations of Magnetic Resonance Imaging in Diagnosis and Treatment. Arthritis Rheum., 2002, 46, 1634–42.

[37]

Yamada, I.; Nakagawa, T.; Himeno, Y.; Numano, F.; Shibuya, H.Takayasu Arteritis: Evaluation of the Thoracic Aorta with CT Angiography. Radiology, 1998, 209, 103–9.

[38]

Arnaud, L.; Naroche, J.; Malek, Z.; Archambaud, F.; Gambotti, L.; Grimon, G.; Kas, A.; Costedoat-Chalumeau, N.; Cacoub, P. Is (18) F-Fluorodeoxyglucose Positron Emission Tomography Scanning a Reliable way to Assess Disease Activity in Takayasu Arteritis? Arthritis Rheum., 2009, 60, 1193–200.

[39]

Schmidt, W. Role of Ultrasound in the Understanding and Management of Vasculitis. Ther. Adv. Musculoskelet. Dis., 2014, 6, 39–47.

[40]

Andrews, J.; Al-Nahhas, A.; Pennell, D.J.; Hossain, M.S.; Davies, K.A.; Haskard, D.O.; Mason, J.C. Non-invasive Imaging in the Diagnosis and Management of Takayasu’s Arteritis. Ann. Rheum. Dis., 2004, 63, 995–1000.

[41]

Fritsch, S.; Copes, R.M.; Savioli, B.; Aguiar, M.F.; Ciconelli, R.M.; Azevedo, V.F, de Souza AW. Translation and Validation of the Indian Takayasu Clinical Activity Score (ITAS2010) for the Brazilian Portuguese Language. Adv. Rheumatol., 2019, 59, 43.

[42]

Park, M.C.; Lee, S.W.; Park, Y.B.; Lee, S.K. Serum Cytokine Profiles and their Correlations with Disease Activity in Takayasu’s Arteritis. Rheumatology, 2006, 45, 545–8.

[43]

Watson, L.; Brogan, P.; Peart, I.; Landes, C.; Bames, N.; Clear, G. Diagnosis and Assessment of Disease Activity in Takayasu Arteritis: A Childhood Case Illustrating the Challenge. Case Rep. Rheumatol., 2014, 2014, 603171.

[44]

Maksimowicz-McKinnon, K.; Bhatt, D.L.; Calabresse, L.H. Recent Advances in Vascular Inflammation: C-reactive Protein and other Inflammatory Biomarkers. Curr. Opin. Rheumatol., 2004, 16, 18–24.

[45]

Kong, X.; Sun, Y.; Ma, L.; Chen. H.; Wei, L.; Wu, W. The Critical Role of IL 6 in the Pathogenesis of Takayasu Arteritis. Clin. Exp. Rheumatol., 2016, 34(Suppl 97):S21–7.

[46]

Sun, Y.; Ma, L.; Yan, F.; Liu, H.; Ding, Y.; Hou. J.; Jiang, L. MMP-9 and IL-6 are Potential Biomarkers for Disease Activity in Takayasu’s Arteritis. Int. J. Cardiol., 2012, 156, 236–8.

[47]

Seo, P.; Stone, J.H. The Antineutrophil Cytoplasmic Antibodyassociated vascultides. Am. J. Med., 2004, 117, 39–50.

[48]

Xu, X.; Akay, A.; Wei, H.; Wang, S.; Murphy, B.P.; Erlandsson, B.E.; Li, X.; Lee, W.G. Advances in smatphone-based Point-of Care Diagnostics. Proc. IEEE, 2015, 103, 236–48.

[49]

Scully, G.C.; Lee, J.; Meyer, J.; Gorbach, A.M.; Fraser, D.G.; Mendelson, Y.; Chon, K.H. Physiological Parameter Monitoring from Optical Recordings with a Mobile Phone. IEEE Trans. Biomed. Eng., 2012, 59, 303–6.

[50]

Wadhawan, T.; Situ, N.; Rui, H.; Lancaster, K.; Yuan, X.; Zouridakis, G. Implementation of the 7-point Checklist for Melanoma Detection on Smart Handheld Devices. Proc. IEEE Eng. Med. Biol. Soc., 2011, 2011, 3180–3.

[51]

Kim, T.S.; Yoon, G.; Lee, J.; Shin, S. Method of Extracting Region of Interest from Tongue Image and Health Monitoring Method and Apparatus Using the Tongue Image. Europe, 2004, 2004, EP1450287A2.

[52]

Larson, E.C.; Goel, M.; Boriello, G.; Heltshe, S.; Rosenfeld, M.; Patel, S.N. SpiroSmart: Using a Microphone to Measure Lung Function on a Mobile Phone. Proc. ACM Conf Ubiquitous Comput., 2012, 1, 280–9.

[53]

Wu, G.; Mahajan, N.; Dhawan, V. Acknowledged Signatures of Matrix Metalloproteinases in Takayasu’s Arteritis. Biomed. Res. Int., 2014, 2014, 827105.

[54]

Matsuyama, A.; Sakai, N.; Ishigami, M.; Hiraoka, H.; Kashine, S.; Hirata, A;. Nakamura, T.; Yamashita, S.; Matsuzawa, Y. Mtrix Metalloproteinases as Novel Disease Markers in Takayasu Arteritis. Circulation., 2003, 108, 1469–73.

[55]

Mahajan, N.; Dhawan, V.; Sangwan, S.; Jain, S. Serum Levels of Soluble Receptor for Advanced Glycation end Product (sRAGE) in Takayasu’s Arteritis. Int. J. Cardiol., 2010, 145(3), 589–91.

Share
Back to top
INNOSC Theranostics and Pharmacological Sciences, Electronic ISSN: 2705-0823, Published by AccScience Publishing